Personalized targeted and immunotherapy
Traditional molecular profiling assessments have limitations in terms of covering genetic variants, often requiring separate tests for each biomarker. Comprehensive molecular profiling of the tumor genome can uncover multiple tumor vulnerabilities and resistance mechanisms in a single step. This information can then be used by specialists to select the most appropriate and effective treatment strategy, minimizing the risks of treatment failure and the toxicity associated with ineffective therapies.
CellDx – a minimally invasive diagnostic test designed for in-depth molecular profiling of tumor genomes, supporting the selection of the most effective targeted and immunotherapy options for patients with any type of solid tumors
Based on the tumor tissue analysis
Based on the tumor tissue analysis
- For professional use only
- Developed, validated and certified by Datar Cancer Genetics
Advantages
Assesses all NCCN-recommended molecular biomarkers
Evaluates additional clinically relevant biomarkers
Helps guide treatment decisions in both labeled and off-label conditions
Advanced Technology
CellDx evaluates the key elements and characteristics that support and drive the progression of malignant tumors, specifically molecular disruptions and their dynamics.
CellDx detects four major classes of genomic alterations that contribute to cancer progression:
Single Nucleotide Variants (SNVs), insertions/deletions (InDels), copy number alterations (CNAs), fusions/rearrangements, translocations
Tumor Mutational Burden (TMB)
Microsatellite Instability (MSI)
PD-L1 Status
SNVs | INDELs
392 Genes
CNAs
333 Genes
FUSIONs
51 Genes
TMB
PD-L1
MSI | MMR
SNV: Single Nucleotid Variation I INDEL: Insertion / Deletion I CNAs: Copy Number Alteration I MSI: Microsatellite Instability I MMR: Mismatch Repair
- CellDx is independent of classic determinants such as the primary organ, histological subtype, morphology (degree of malignancy), aggressiveness, and stage of the disease
Clinical Efficacy
The clinical benefit of CellDx in guiding the selection of personalized, safe, and effective cancer treatment regimens has been convincingly demonstrated in robust clinical trials and case reports (see the Scientific Publications section).
Indications
- Targeted TherapyComprehensive evaluation of molecular biomarkers according to the latest NCCN Clinical Practice Guidelines
- ImmunotherapyAnalysis of microsatellite instability (MSI), tumor mutational burden (TMB), and PD-L1 status (22C3 and 28-8). Additional PD-L1 SP142 testing is available for non-small cell lung cancer and urothelial carcinoma.
Biomarker-Based Drug Applications (Examples)
Decided to take the CellDx!
Decided to take the CellDx!
Book your first consultation with a doctor
The doctor will inform you about the upcoming testing, answer any questions you may have, and then ask you to sign an informed consent form for the test. Then, the doctor will complete a special form (application) according to the requirements of Datar Cancer Genetics
The doctor will inform you about the upcoming testing, answer any questions you may have, and then ask you to sign an informed consent form for the test. Then, the doctor will complete a special form (application) according to the requirements of Datar Cancer Genetics
Deliver the tissue sample fixed in formalin to any of the Sample Collection Center ALFA Diagnostica (see below)
Book your second consultation with the doctor
The doctor will interpret your test results, answer any questions you have, and provide recommendations for your next steps
The doctor will interpret your test results, answer any questions you have, and provide recommendations for your next steps
Formalin-fixed tissue sample, FFPE block (tumor content ≥5%) or 10 unstained slides
Transported by accredited carrier DHL in a specialized container at a temperature of +2°C to +6°C to the Datar Cancer Genetics laboratory in the UK
Where can I get tested?
Chisinau
21 N. Теstemițanu, street
Monday – Tuesday, 07:30 - 14:30 I Wednesday, 07:30 - 09:00
Monday – Tuesday, 07:30 - 14:30 I Wednesday, 07:30 - 09:00
Laboratory Report
The test results provided in the laboratory report are intended for professional use only by qualified specialists, considering the
capabilities/limitations/characteristics of the test, the patient's current health status, clinical history, and diagnostic data.
capabilities/limitations/characteristics of the test, the patient's current health status, clinical history, and diagnostic data.
VIEW SAMPLE REPORTS
Book a medical consultation with an expert
Professional and attentive care for each patient
Rusnac Angela
Oncologist
Professional experience 32 years, the highest category
Professional experience 32 years, the highest category
Cost and terms
Cost, in MDL
CellDx – Comprehensive molecular profiling of solid tumors for the personalization of targeted and immunotherapy
44 000
Working days
15
Test Name
Frequently asked questions
All key genomic indicators along with descriptions of potential therapeutic options
SNVs, INDELs, CNAs, Fusions, TMB, PD-L1, MMR, HRD (homologous recombination deficiency)
Yes, Celldx can provide information about target alterations
Celldx enables informed decisions on the appropriateness of immunotherapy by using genomic signatures such as tumor mutation burden (TMB) and PD-L1 status through immunohistochemistry
Scientific publications
Published by: Datar Cancer Genetics
Published Year: 2023
Published Year: 2023
Published by: Datar Cancer Genetics
Published Year: 2023
Published Year: 2023
Published by: Datar Cancer Genetics
Published Year: 2023
Published Year: 2023
Do you have questions?
Call or send us a question
© 2024 Oncogene & ALFA Diagnostica. All rights reserved.
Designed by Targetolog.md.
Designed by Targetolog.md.